Only 25% Patients Stick With Novo Nordisk's Wegovy Or Ozempic After 2 Years, A Study Shows; Company Calls Data Insufficient
Only 25% Patients Stick With Novo Nordisk's Wegovy Or Ozempic After 2 Years, A Study Shows; Company Calls Data Insufficient
一項研究顯示，只有25％的患者在使用諾和諾德的Wegovy或Ozempic兩年後繼續使用；公司稱數據不足。
An analysis of U.S. pharmacy claims data reveals that only one in four patients prescribed Novo Nordisk A/S's (NYSE:NVO) weight-loss drugs, Wegovy and Ozempic, continue their treatment after two years.
根據美國藥房索賠數據的分析，僅有四分之一的給予諾和諾德A/S（紐交所：NVO）減重藥Wegovy和Ozempic處方的患者持續了兩年的治療。
The data provided to Reuters highlights a significant decline in long-term adherence to these medications.
路透社提供的數據突顯了這些藥物長期依從性的顯著下降。
The analysis, conducted by Prime Therapeutics and Magellan Rx Management, offers a longer view of real-world usage compared to previous research, according to the exclusive Reuters report.
Prime Therapeutics和Magellan Rx Management進行的分析提供了比以前的研究更長期的真實世界使用情況，這是路透社的獨家報道。
Also Read: Eli Lilly's Mounjaro Outpaces Novo Nordisk's Ozempic In Weight Loss Effectiveness, Study Shows.
此外閱讀：禮來公司的Mounjaro在減重效果上超越諾和諾德的Ozempic，研究表明。
Prime Therapeutics and Magellan...
Prim...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。